Indication
Treatment of ambulatory patients aged 3 to 7 years old with Duchenne muscular dystrophy
Loading your page…
Loading your page…
Muscular Dystrophy, Duchenne
Marketing Authorisation Holder: Roche Registration GmbH
INN: delandistrogene moxeparvovec
AI Drug & Interaction Analysis
Free account required
Ask Osler about Elevidys: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.